Genomic Features of Homologous Recombination Deficiency in Breast Cancer: Impact on Testing and Immunotherapy
Genes · 26.01.2024 · 15 (2) · 162
DOI: 10.3390/genes15020162 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Genes, online erschienen am 26.01.2024. Verfasst von Umer Ali und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biological Sciences, Tennessee State University, Nashville, TN 37209, USA. Hauptthemen laut MEDLINE: Breast Neoplasms. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 157 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, NCI NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Genomic instability is one of the well-established hallmarks of cancer. The homologous recombination repair (HRR) pathway plays a critical role in correcting the double-stranded breaks (DSB) due to DNA damage in human cells. Traditionally, the BRCA1/2 genes in the HRR pathway have been tested for their association with breast cancer. However, defects in the HRR pathway (HRD, also termed ‘BRCAness’), which has up to 50 genes, have been shown to be involved in tumorigenesis and treatment susceptibility to poly-ADP ribose polymerase inhibitors (PARPis), platinum-based chemotherapy, and immune checkpoint inhibitors (ICIs). A reliable consensus on HRD scores is yet to be established. Emerging evidence suggests that only a subset of breast cancer patients benefit from ICI-based immunotherapy. Currently, albeit with limitations, the expression of programmed death-ligand 1 (PDL1) and tumor mutational burden (TMB) are utilized as biomarkers to predict the favorable outcomes of ICI therapy in breast cancer patients. Preclinical studies demonstrate an interplay between the HRR pathway and PDL1 expression. In this review, we outline the current understanding of the role of HRD in genomic instability leading to breast tumorigenesis and delineate outcomes from various clinical trials. Furthermore, we discuss potential strategies for combining HRD-targeted therapy with immunotherapy to achieve the best healthcare outcomes in breast cancer patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biological Sciences, Tennessee State University, Nashville, TN 37209, USA.
- Meharry-Vanderbilt Alliance, Vanderbilt University Medical Center, Nashville, TN 37209, USA.
- Department of Pharmacology, Vanderbilt University, Nashville, TN 37209, USA.
ORCID-Profile: Venkataswarup Tiriveedhi
Förderung
- NIH HHS
- NCI NIH HHS
- National Institutes of Health
Zitieren
APA
Ali, U., Vungarala, S., & Tiriveedhi, V. (2024). Genomic Features of Homologous Recombination Deficiency in Breast Cancer: Impact on Testing and Immunotherapy. Genes, 15(2), 162. https://doi.org/10.3390/genes15020162
Vancouver
Ali U, Vungarala S, Tiriveedhi V. Genomic Features of Homologous Recombination Deficiency in Breast Cancer: Impact on Testing and Immunotherapy. Genes. 2024;15(2):162. doi:10.3390/genes15020162
BibTeX
@article{Ali2024,
author = {Ali, Umer and Vungarala, Sunitha and Tiriveedhi, Venkataswarup},
title = {Genomic Features of Homologous Recombination Deficiency in Breast Cancer: Impact on Testing and Immunotherapy},
journal = {Genes},
year = {2024},
volume = {15},
number = {2},
pages = {162},
doi = {10.3390/genes15020162}
}
EUVIMED